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Résumé en
anglais
OBJECTIVE: Since HAART, primary liver cancer has emerged as an increasing
cause of morbidity and mortality in patients with HIV infection. Our aim was to
compare characteristics and outcome of primary liver cancer according to HIV
status in HCV cirrhotic patients submitted to periodic ultrasonographic
surveillance.
METHODS: All patients with primary liver cancer and cirrhosis were selected from
two prospective cohorts (ANRS CO12 Cirvir, viral cirrhosis, n=1081; ANRS CO13
Hepavih, HIV-HCV coinfection, n=1175). Cirrhosis was diagnosed by liver biopsy in
monoHCV group and biopsy and/or non-invasive tests in HIV-HCV group.
Ultrasonographic surveillance was performed every 6 months. Diagnosis of primary
liver cancer was established according to EASL-AASLD guidelines.
RESULTS: Primary liver cancer was diagnosed in 32 patients, 16 in each group,
and corresponded to hepatocellular carcinoma in all except for two
cholangiocarcinomas in HIV-HCV patients. Ultrasonographic follow-up was similar
(median time since last ultrasonographic without focal lesion: 237 days in HIV-HCV
group (n=12) versus 208 days in HCV group, NS). At primary liver cancer diagnosis
HIV-HCV patients were markedly younger (48 vs. 60 yrs, P<0.001), primary liver
cancer was more advanced in HIV-HCV patients (single nodule: 43% vs. 75%,
P=0.07; mean diameter of main nodule: 24 vs. 16 mm, P=0.006; portal obstruction:
3 vs. 0). Curative treatment was performed in four HIV-HCV patients versus 11
HCV patients (P=0.017). During follow-up, 10 HIV-HCV patients died versus only
one HCV patient (P=0.0005).
CONCLUSIONS: This result suggests more aggressiveness for tumors in HIV







































Publié sur Okina (http://okina.univ-angers.fr)
